Evidence suggests that myelin alterations could predispose to schizophrenia. Reduced expression of several myelin genes has been observed in schizophrenia patients. Recently, we identified the discoidin domain receptor 1 (DDR1; located at human chromosome 6p21.3) as a myelin gene in the mouse model and in a human oligodendroglial cell line. In the present study we screened for single nucleotide polymorphisms (SNPs) in the DNA from 100 schizophrenia patients. We identified a novel mutation within exon 10 that produces the amino-acid substitution N502S in the a-d isoforms, and M475V in the e isoform. However the frequency of the mutation (2%) was similar in schizophrenia patients and in control subjects. In a casecontrol assessment with 389 schizophrenic patients and 615 controls, we identified one SNP (SNP9, rs1049623) associated with schizophrenia (odds ratio = 1.44, 95% confidence interval: 1.15-1.79, adjusted P = 0.0016). This association was confirmed in haplotype analysis; the SNPs 9-10-11 (rs1049623, rs2267641 and rs2239518) haplotype remaining significant even after adjustment for multiple testing (adjusted P = 0.0136). Of note was a strong gender dependence in the association, that is, statistical significance restricted to men (adjusted P-value = 0.0002). Regression analysis of DDR1 mRNA expression in peripheral blood lymphocytes from schizophrenia patients showed that the presence of the G allele significantly decreased the relative number of mRNA copies in a dose-dependent manner (P = 0.003). These data suggest that the risk haplotype tags a cis-acting variant involved in the transcription regulation system of the gene. In conclusion, we propose the DDR1 as a new susceptibility gene for schizophrenia.
Introduction
Schizophrenia is a complex brain disorder affecting approximately 1% of the general population, worldwide. Although genetic factors are known to play an important role, a generally accepted model for the pathogenesis of this disease has yet to be identified. Genome-wide linkage scans and genetic association studies have identified several, rather broad, chromosomal regions as the sites of potential susceptibility genes for schizophrenia. 1 One of the three bestsupported regions is 6p24-21; 2 the chromosomal region that contains the major histocompatibility complex I (MHC I) and one of the most gene-dense regions of the human genome. Several gene loci in this region have been found to be putatively associated with schizophrenia. These are dysbindin 1 (DTNBP1, 6p22.3), 3 myelin oligodendrocyte glycoprotein (MOG, 6p22.1), 4 tumour necrosis factor alpha (TNF-a, 6p21.3), [5] [6] [7] the notch type-4 receptor (NOTCH4, 6p21.3) [8] [9] [10] [11] [12] and tenascin B (TNXB, 6p21.3). 13 Among these, DTNBP1 is the gene most consistently replicated and, positive findings have been obtained in independent data sets; albeit no single haplotype having been shown to be in common across all the samples. 3 Pathogenic mutations have not been identified as yet, but risk haplotypes have been observed to be associated with reduced levels of DTNBP1 mRNA expression in brain. 14 The chromosomal region 6p21.3 contains other putative candidate genes for schizophrenia, including the locus coding for the discoidin domain receptor 1 (DDR1). This receptor belongs to the DDRs subfamily of tyrosine kinase receptors and is distinguished by an extracellular domain homologous to the carbohydrate-binding lectin discoidin-I in Dictyostelium discoideum. 15 The discoidin homology domain is also present in several membrane-bound, and secreted, proteins. 16 Among these are neuropilins and contactin-associated proteins 1 and 2, which are involved in the development of the nervous system 17, 18 and the XLRS-1 gene which, when mutated, causes the human X-linked inherited disease retinoschisis. 19 Collagen is the unique DDR1 ligand identified to-date and, after binding to the receptor, it follows very slow activation kinetics. 15 Five isoforms of DDR1 generated by alternative splicing have been identified; 20 the nomenclature involving the suffixes a-e. DDR1 is ubiquitously expressed at low levels in a variety of epithelial tissues (e.g. heart, placenta, muscle, kidney and pancreas) and with high levels of expression in the brain. 15 It is significantly overexpressed in several tumours, particularly in breast, ovarian and brain cancers. In situ hybridization studies in mice have demonstrated expression of DDR1 in the central nervous system (CNS) in embryonic stages as well in adulthood, particularly in proliferating neuroepithelia. 21, 22 In CNS, collagen-DDR1 signalling has been shown to be essential for granule neuron-axon formation. 23 In addition, we reported the expression of DDR1 in oligodendrocytes during mouse brain development and in a human oligodendroglial cell line; these data provide evidence for the potential involvement of DDR1 in the myelination process. 24 Classically, schizophrenia investigation has tended to focus on neuron function, but, increasingly, data have been produced to support the hypothesis that white matter oligodendrocytes are also important in the development of the disease. [25] [26] [27] [28] [29] In view of on the chromosomal localization of DDR1 together with its putative role in the CNS development and in oligodendrocyte function, we evaluated DDR1 as a candidate gene for schizophrenia. In the present study, we initially performed a mutation screening by direct sequencing of the coding regions of DDR1 in 100 patients with schizophrenia. Subsequently, we sought evidence for association between the DDR1 locus and schizophrenia in a large case-control Spanish population sample. We then measured mRNA expression in peripheral blood lymphocytes (PBL) from 30 patients grouped according to their DDR1 genotype.
Materials and methods

Subjects
A total of 1004 unrelated Caucasians born in Spain were recruited. The population study sample consisted of 389 patients with schizophrenia (252 men and 137 women) from the referral Hospital Psiquiàtric Universitari Institut Pere Mata (Reus, Spain) and 615 control individuals (321 men and 294 women). Mean age of the patients was 51.4 years (range: 19-88) and the average duration of illness was 27 years (range: 1-64). All cases met DSM-IV criteria for the diagnosis of schizophrenia, and the schizoaffective disorder was excluded. Patients recruited between 1996 and 1998 were evaluated by at least two psychiatrists, with a consensus on diagnosis being reached between them. Patients recruited between 2001 and 2004, were evaluated with the schedules for clinical assessment in neuropsychiatry (SCAN). 30 Data from the family history of psychosis in first-degree relatives, the course of the illness, the onset type and the predominant symptomatology were dichotomized to facilitate subsequent statistical analysis, as described elsewhere. 31 Control individuals were recruited from primarycare centres in the same geographical area as the referral hospital. The mean age was 43.1 years (range: 18-75). Screening for psychiatric diseases was performed according to the 28-scaled global health questionnaire (GHQ) 32 and an interview conducted by a physician to provide a full medical history and details on lifestyle, habits and antecedents. Diseases were recorded according to the International Classification of Diseases Version 9 (ICD9). Only unrelated citizens with no personal history of psychiatric disease and a GHQ score < 7 were considered for inclusion into the study. The percentage of excluded participants was gender-independent.
The study complied with the guidelines of the Medical Ethical Committee from each of the participating institutions. Informed consent was obtained from all participants and anonymity of data was guaranteed.
DNA extraction
Genomic DNA was prepared from venous blood samples using the Puregene DNA purification kit (Gentra Systems, Barcelona, Spain). DNA was diluted to a concentration of 50 ng/ml, unless otherwise specified.
Isolation and cryopreservation of PBL Lymphocytes were isolated from heparinized fresh blood using the Ficoll-Paque reagent (Amersham Biosciences, Barcelona, Spain) within 6 h of blood withdrawal. Density gradient isolated PBL were resuspended in fetal bovine serum with 10% dimethylsulphoxide (Sigma-Aldrich, Madrid, Spain). Aliquots of cell suspension were transferred to cryotubes, frozen overnight at a rate of 11C/min in a freezer at À801C and transferred within 24 h to a freezer at À1501C. Cells were thawed for use in the presence of TRIzol reagent (Invitrogen, Barcelona, Spain), as described later.
Mutation identification DDR1 genomic sequence AC004211.1 was used to design primers using Primer3 software. 33 The sample for mutation screening of the coding regions consisted of 100 randomly selected patients with schizophrenia (53 men and 47 women). Genomic DNA concentration was measured in triplicate using the Picogreen fluorescent assay according to the manufacturer's protocol (Molecular Probes, Barcelona, Spain). Samples were combined in pools of 10 at a final concentration of 2.5 ng/ml. The DNA pools were amplified by PCR and the amplicons were sequenced in both directions using the DYEnamic ET Terminator Cycle Sequencing Kit and the MegaBACE1000 sequencer, according to the manufacturer's instructions (Amersham Biosciences, Barcelona, Spain). Chromatograms were analysed by the Sequencher program (Gene Codes Corporation, Ann Arbor, MI, USA). When a putative mutation was detected, all 10 individual samples that constituted the pool were sequenced individually. Details of markers and PCR conditions are available on request from the corresponding author. Mutation nomenclature described by den Dunnen and Antonarakis 34 was used to annotate the mutations.
SNP genotyping
A total of 22 single nucleotide polymorphisms (SNPs) spanning > 20 kb in the DDR1 locus were selected from among those identified in the mutation screening analysis and from the Celera database (http:// www.celeradiscoverysystem.com). However, only 15 (8 plus 7) fit the conditions imposed by the analysis system (see below). An additional SNP was included from the neighbouring gene GTF2H4 (Figure 1 ).
Genotyping was performed using the MassARRAY system according to the manufacturer's instructions (Sequenom Inc., San Diego, CA, USA) as described previously. 35 Assay design and PCR conditions are available on request from the corresponding author. As quality control, SNP rs1049628 was genotyped twice using two different assays. Concordance was 100%.
To check for evidence of population admixture at the genome level, 25 unlinked genome-spread SNP markers, all with minor allele frequency > 10%, were analysed in the DNA of all participants using restriction enzyme digestion of PCR products followed by gel analysis. Details of markers and PCR conditions are available on request from the corresponding author.
Quantification of DDR1 expression by real-time RT-PCR Total RNA was extracted using TRIzol Reagent (Invitrogen, Barcelona, Spain) from frozen PBL. Ten schizophrenia patients from each of the three SNP9 genotypes were selected; 20 men and 10 women. The purity and concentration of RNA were estimated by the relative spectrometric absorbance at 260/280 nm. Human brain polyA þ RNA was purchased from Clontech (BD Biosciences, Barcelona, Spain) as a pool of whole brains from three normal male (mean age 55.6 years) and three normal female (mean age 46 years) Caucasians whose death had been caused by trauma. One microgram of total RNA or 1 ng of polyA þ RNA was reverse transcribed to cDNA using random hexamers and SuperScript II Rnase H À reverse transcriptase according to the manufacturer's instructions (Invitrogen, Barcelona, Spain). DDR1 mRNA expression was quantified by real-time quantitative PCR with the use of an ABI Prism 5700 Sequence Detector System (Applied Biosystems, Barcelona, Spain) combined with a dual-label fluorogenic detection system TaqMan (Applied Biosystems, Barcelona, Spain) based upon the 5 0 nuclease assay. The 18S RNA was used as internal control. TaqMan primers and probes for DDR1 and 18S RNA were obtained from pre-designed Assays-on-Demand products (Applied Biosystems, Barcelona, Spain) and validated. PCR amplifications were performed in triplicate with cDNA samples in a 25 ml volume. DDR1 mRNA expression for each sample was calculated using the 2 ÀDDC t method according to the manufacturer's instructions (Applied Biosystems, Barcelona, Spain). The amounts of DDR1 transcripts in each sample are calculated relative to the levels in the calibrator pool, and are dimensionless numbers.
Statistical analysis
Hardy-Weinberg equilibrium, linkage disequilibrium (LD) estimates, and allelic association tests for individual SNPs were calculated using Haploview 3.0.
36 COCAPHASE 37 was used to estimate haplotype frequencies by the EM algorithm and to perform tests of haplotype association. For the haplotype analysis, we analysed three marker haplotypes from adjacent SNPs using the 'sliding-window' technique. Haplotypes at frequencies < 5% were grouped together before applying the test. Correction for multiple testing was done by comparing the unadjusted P-values with the distribution of the best-P-value for any SNP following 100 000 permutations; the 'case' and 'control' labels being randomly reassigned to the actual data using Haploview. Since the permutations occur at the genotype level, the LD relationships among SNPs are implicitly considered in the permutation test. The same procedure was performed using COCAPHASE to adjust the P-value of the best result in the case of haplotypes, following 10 000 permutations. The STRUCTURE 2.0 program 38 was used to test for population stratification. NetGene2 Server 39 and Splice Site Prediction by Neural Network 40 were used to predict if new splice sites were created by the identified mutations. Regression analysis was used to compare levels of mRNA between groups using the SPSS program (version 13.0).
Results
Mutation analysis of DDR1 in schizophrenia
To identify common sequence variants of the DDR1 gene, we sequenced the coding regions and the exonintron boundaries of DDR1 in 10 pools of DNA from blood samples of 100 non-related schizophrenic patients. Sixteen SNPs and one 2 bp deletion were identified. Of these, 10 had been reported in public databases (dbSNP) and seven were new (Table 1 ). . This variant has a very low allelic frequency of about 2%, and is similar in patients and control subjects. No homozygote for the rare G allele was observed in the whole study sample. Alignment of human, rat and mouse sequences showed that N502 is conserved. Exons 10, 11 and 12 codify for the juxtamembrane region of the receptor, and which contains the consensus sequence NPXY for tyrosine phosphorylation involved in receptor signal transduction. Neither the four SNPs identified in exon-intron boundaries nor the 2 bp deletion create new splicing sites.
DDR1 haplotype effects on risk of schizophrenia To assess whether there was a genotype or haplotype effect of DDR1 on schizophrenia risk, we performed a case-control association study. We included a total of 16 SNPs spanning > 20 kb in the DDR1 region and, of these, eight were identified in the DDR1 mutational screening in schizophrenia and eight derived from dbSNP (seven covering the DDR1 5 0 and 3 0 gene ends and one SNP in the neighbouring gene GTF2H4, see Figure 1 ). SNP1 was not included in the statistical analysis because allele calling did not reach 85%. SNP12 was monomorphic in our study sample and was also excluded from the statistical analysis. All SNPs included in the analysis were in HardyWeinberg equilibrium (data not shown). Strong LD (D 0 X0.95) was observed between all markers with allelic frequencies > 0.05. Frequencies of alleles derived from the 16 polymorphisms are shown in Table 2 . Following adjustment for multiple testing by permutation analysis (100 000 permutations) only SNP9 (rs1049623) remained statistically significant (adjusted P = 0.013) ( Table 2 ). The odds ratio (OR) for SNP9 was 1.44 and a 95% confidence interval (CI): 1.15-1.79 (P = 0.0016). Of note was that there was a dose-dependent effect between SNP9 and schizophrenia, that is GG homozygote subjects had an OR = 2.26 (95% CI: 1.30-3.91), GA heterozygote subjects had an OR = 1.34 (95% CI: 1.00-1.79); assuming that for AA homozygote subjects the OR was 1.
We then estimated the haplotypes and performed an association analysis with three consecutive SNPs using the 'sliding window' approach. Table 3 summarizes the P-values and the adjusted P-values of the best-result outcomes in the homogeneity likelihood ratio test. Non-adjusted P-values were < 0.05 for three haplotypes (SNP4-SNP5-SNP6, SNP8-SNP9-SNP10, SNP9-SNP10-SNP11) with the 9-10-11 being the most significant, statistically. This significance remained even after adjustment for multiple testing (adjusted P = 0.0136). Estimated haplotype frequencies of the SNPs 9-10-11 window are shown as Supplementary material (SM Table) at the end of the text.
To exclude the possibility that the positive association was due to genetic stratification among patients and control subjects, we performed a genetic stratification analysis according to the method of 
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Discoidin domain receptor 1 and schizophrenia B Roig et al Pritchard. 37 Using 25 independent bi-allelic markers with minor allele frequencies > 10%, we were unable to detect genetic stratification (data not shown).
We repeated the association analyses stratifying the sample by gender. The comparison between male subgroups revealed a more significant association between SNP9 and schizophrenia than in the overall study sample (frequency of the G allele in cases 0.323 versus 0.190 in controls, adjusted P-value < 0.00001, OR = 2.03, 95% CI: 1.51-2.73). At the haplotype level, window 9-10-11 was, again, the most significant result (adjusted P = 0.0002). By contrast, there were no significant differences between female cases and controls at any SNP or haplotype (P-value = 0.426 for SNP9, frequency of the G allele 0.225 versus 0.252 in cases and controls, respectively). Finally, we assessed the effect of SNP9 on clinical variables in the patient group and found no statistically significant associations.
DDR1 mRNA expression analysis in PBL To date, there has been a paucity of data on expression of DDR1 in human brain. Hence, we examined DDR1 expression levels in human brain and PBL using real-time RT-PCR with an assay that detects all DDR1 isoforms. The amount of DDR1 mRNA copies in the pool of polyA þ RNA from brain was 18-times greater than in mRNA from PBL obtained from control participants (P = 0.0001) (Figure 2a) . Frozen PBL samples from 30 schizophrenia patients were grouped according to SNP9 genotype and the DDR1 mRNA copies were measured (Figure 2b) . Linear regression analysis, with gender, age and SNP9 genotype as independent variables, showed a significant association of DDR1 expression and SNP9 genotype (P = 0.003). Although in men there was a trend towards lower levels of DDR1 expression, gender did not enter as a statistically significant variable in the equation (P = 0.085). Age was not associated with DDR1 expression (P = 0.152). Schizophrenia patients homozygous for the SNP9 G allele had decreased expression of DDR1 compared to those who were GA heterozygous and who, in turn, had less than those who were AA homozygous (P = 0.003) (Figure 2b) .
Discussion
In the present study we propose DDR1 as a new candidate gene for susceptibility to schizophrenia. Abbreviations: CI, confidence interval; MFA, most frequent allele; Nr, not reported; NS, not significant; OR, odds ratio. a P-value adjusted for multiple testing by 100 000 permutations; MFA SNP1 (rs1264327) was excluded from the analysis because of technical failure in genotyping and SNP12 (rs2301755) was monomorphic in our population sample. Located at 6p21.3, mutation analysis of the coding region of the gene in the DNA from 100 schizophrenia patients did not reveal any putative disease mutation. We found 17 polymorphisms: 10 SNPs already reported in the public databases, one new 2 bp intronic deletion and six new SNPs. The only two missense mutations, both located in exon 10, had similar allele and genotype frequencies in schizophrenia patients as in the control group of subjects. This observation does not definitively rule out their involvement in the pathogenesis of schizophrenia but does make it highly unlikely. The mutation N502S does, however, deserve further investigation to determine whether it can have an influence either on the phosphorylation of tyrosine at amino-acid position 513 or on the protein conformation at the neighbour- This result may be considered as a reinforcement of the proposition that DDR1 could be a real susceptibility gene for the disease, 41 under an additive model. The 'sliding window' haplotype analysis approach for three consecutive SNPs confirmed this result; the strongest haplotype association being composed of SNPs 9, 10 and 11.
Gross genetic stratification was not observed in our case-control sample (assessed by the Pritchard method) and this finding decreases the possibility of false positives in our analyses. We need to bear in mind, however, that a minor degree of stratification would not be detected with the 25 SNPs we had used.
We found a clear gender-related genetic effect on the association with schizophrenia and which was restricted to men. Of note was that the frequency of the G allele at SNP9 is under-represented in control men compared to control women (0.190 versus 0.252) although statistically not significant (adjusted P = 0.0878). Genetic association with schizophrenia restricted to one or other of the genders has been reported previously [42] [43] [44] and might be related to gender-specific differences in the schizophrenia phenotype itself. In Shifman et al. 43 (above) there were also differences in frequencies between male and female control subjects.
The positive association of DDR1 with schizophrenia could be due to LD between DDR1 and other candidate genes on chromosome 6p, which have been reported to be associated with schizophrenia (i.e. MOG, TNF, NOTCH4 and the MHCI locus). We may assume that the association that we had detected was not due to LD in any of these other loci since DDR1 is separated from the respective haplotype blocks by recombination hotspots. 45 Moreover, the MHCI locus (which is one of the most complex regions in terms of LD pattern 46 and, therefore, LD in this region can only be explored by dense-marker analysis), was not found to be associated with schizophrenia in an analysis involving a sample of German patients affected with the disease. 47 Expression analysis in PBL showed that the patients with the SNP 9 GG risk genotype had significantly decreased levels of DDR1 mRNA. This finding suggests that a functional, as yet unidentified, mutation affects the transcription regulatory system by decreasing transcription, or increasing the rate of mRNA degradation, or both.
We had previously observed that, in mice, the expression of DDR1 is high in oligodendrocytes, and is of considerable importance during the myelination period. 24 If a similar expression pattern occurs in the human brain, then DDR1 could be involved in the myelin abnormalities observed in schizophrenia. 25, 48 Brain-imaging studies, as well as post-mortem exam- Linear regression analysis with gender, age and SNP9 genotype as independent variables showed a significant association of DDR1 expression and SNP9 genotype (P = 0.003). Although men showed a trend towards lower levels of DDR1 expression, the gender variable did not significantly enter into the equation (P = 0.085). Age was not associated with DDR1 expression (P = 0.152). Schizophrenia patients homozygous for the SNP9 G allele (N = 10) had decreased expression of DDR1 compared to those who were GA heterozygous (N = 10) who, in turn, had less than those who were AA homozygous (N = 10, P = 0.003).
inations, have shown subtle abnormalities in cortical and sub-cortical white matter of patients with schizophrenia. [49] [50] [51] [52] At the molecular level, transcriptional downregulation of oligodendrocyte-and myelin-related genes has been detected through microarray-based analyses in pre-frontal cortex samples from patients with schizophrenia. [53] [54] [55] It is of note that the myelination processes that occur during late-adolescence-to-early-adulthood (the time of peak incidence of schizophrenia onset) are concentrated in the frontal and temporal lobes; brain regions that are critical in the development of schizophrenia. 26, 48 For example, patients with meta-chromatic leukodystrophy, a rare inborn disease of myelin formation, can often present with clinical episodes of psychoses, schizophrenia and other related disorders in the course of adolescence and young adulthood. 56 In summary, we present a novel candidate gene that predisposes to schizophrenia, the DDR1 gene, located at chromosome 6p21.3. We have presented data indicating an association between DDR1 and schizophrenia that is prominent in men. The underlying mechanism is uncertain but, probably, it is via one of the gene regulatory regions since the risk genotype appears to be associated with altered levels of mRNA expression. We believe that our finding warrants confirmatory investigation in other populations, and the underlying molecular mechanism elucidated in vitro.
